Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of "Hold" by Analysts

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) has received an average recommendation of "Hold" from the eleven research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $5.81.

Several brokerages have issued reports on DH. Needham & Company LLC reaffirmed a "hold" rating on shares of Definitive Healthcare in a research note on Tuesday, August 6th. Barclays cut their price objective on shares of Definitive Healthcare from $6.00 to $4.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 7th. Robert W. Baird decreased their target price on shares of Definitive Healthcare from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered shares of Definitive Healthcare from a "neutral" rating to an "underweight" rating and cut their price target for the company from $7.00 to $5.00 in a research report on Wednesday, July 31st. Finally, Stifel Nicolaus decreased their price objective on Definitive Healthcare from $9.50 to $7.50 and set a "buy" rating on the stock in a report on Wednesday, July 31st.

Institutional Investors Weigh In On Definitive Healthcare

A number of institutional investors have recently modified their holdings of DH. Norden Group LLC purchased a new stake in shares of Definitive Healthcare during the first quarter valued at approximately $83,000. SG Americas Securities LLC bought a new position in Definitive Healthcare in the 3rd quarter valued at approximately $84,000. Sanctuary Advisors LLC purchased a new stake in Definitive Healthcare during the 2nd quarter valued at $85,000. Canada Pension Plan Investment Board bought a new stake in shares of Definitive Healthcare in the 2nd quarter worth $109,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Definitive Healthcare by 31.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company's stock worth $116,000 after purchasing an additional 5,083 shares in the last quarter. 98.67% of the stock is owned by hedge funds and other institutional investors.

Definitive Healthcare Price Performance

NASDAQ DH traded up $0.01 on Tuesday, hitting $4.43. The stock had a trading volume of 391,244 shares, compared to its average volume of 783,652. The firm has a 50-day moving average of $4.31 and a 200-day moving average of $5.42. The company has a market capitalization of $522.45 million, a price-to-earnings ratio of -2.53, a price-to-earnings-growth ratio of 6.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.40 and a current ratio of 2.40. Definitive Healthcare has a 52-week low of $3.19 and a 52-week high of $10.62.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported $0.09 earnings per share for the quarter, meeting the consensus estimate of $0.09. Definitive Healthcare had a positive return on equity of 0.98% and a negative net margin of 156.65%. The firm had revenue of $63.70 million for the quarter, compared to analysts' expectations of $63.19 million. During the same quarter last year, the firm posted $0.08 EPS. The company's revenue was up 4.4% compared to the same quarter last year. Equities analysts expect that Definitive Healthcare will post 0.07 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.